

MM1-A
Vol. 20 No. 7

Replaces MM1-P
Vol. 17 No. 21

Molecular Diagnostic Methods for Genetic Diseases;
Approved Guideline

This document provides guidance for the use of molecular biological techniques for clinical detection of heritable mutations associated with genetic disease.

A guideline for global application developed through the NCCLS consensus process.



NCCLS...

Serving the World's Medical Science Community Through Voluntary Consensus

NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

An NCCLS document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus—"proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate (i.e., "tentative") consensus level.

Proposed An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Tentative A tentative standard or guideline is made available for review and comment only when a recommended method has a well-defined need for a field evaluation or when a recommended protocol requires that specific data be collected. It should be reviewed to ensure its utility.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS's established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation.

Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline

Abstract

NCCLS document MM1-A—*Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline*, provides general recommendations for all phases of the operation of a molecular genetics diagnostic laboratory. The recommendations cover nomenclature for human pedigrees and the designation of mutations; laboratory safety; and “front-end” activities, such as intake information, specimen identification and accessioning, and sample preparation. Other topics addressed are molecular analytical techniques, test validation and characterization, quality assurance, results reporting, and selection of referral laboratories. The guideline also includes definitions of selected terms commonly used in the theory and practice of molecular genetics.

NCCLS. *Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline*. NCCLS document MM1-A (ISBN 1-56238-395-7). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA 2000

THE NCCLS consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of NCCLS documents. Current editions are listed in the *NCCLS Catalog*, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the *NCCLS Catalog*, contact the NCCLS Executive Offices. Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: exoffice@nccls.org; Website: www.nccls.org

MM1-A
ISBN 1-56238-395-7
ISSN 0273-3099

Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline

Volume 20 Number 7

Dale H. Altmiller, Ph.D.
Julian Gordon, Ph.D.
Wayne W. Grody, M.D., Ph.D.
Karla J. Matteson, Ph.D.
Patricia D. Murphy, Ph.D.
Walter W. Noll, M.D.
Carolyn Sue Richards, Ph.D.
Alex Wesolowski
Emily S. Winn-Deen, Ph.D.
Freda E. Yoder, M. A.



This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from NCCLS publication MM1-A— *Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline* (ISBN 1-56238-395-7). Copies of the current edition may be obtained from NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request. To request such permission, address inquiries to the Executive Director, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright ©2000. The National Committee for Clinical Laboratory Standards.

Suggested Citation

(NCCLS. *Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline*. NCCLS document MM1-A [ISBN 1-56238-395-7]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2000.)

Proposed Guideline

December 1997

Approved Guideline

April 2000

ISBN 1-56238-395-7

ISSN 0273-3099

Committee Membership

Area Committee on Molecular Methods

Chester J. Herman, M.D., Ph.D.
Chairholder

Grady Memorial Hospital
Atlanta, Georgia

Russel K. Enns, Ph.D.
Vice-Chairholder

Vysis, Inc.
Downers Grove, Illinois

Subcommittee on Molecular Genetics

Dale H. Altmiller, Ph.D.
Chairholder

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Julian Gordon, Ph.D.

Abbott Laboratories
North Chicago, Illinois

Wayne W. Grody, M.D., Ph.D.

UCLA Medical Center
Los Angeles, California

Karla J. Matteson, Ph.D.

University of Tennessee Medical Center
Knoxville, Tennessee

Patricia D. Murphy, Ph.D.

Albany Medical Center
Albany, New York

Walter W. Noll, M.D.

Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Carolyn Sue Richards, Ph.D.

Baylor College of Medicine
Houston, Texas

Alex Wesolowski

Roche Molecular Systems, Inc.
Branchburg, New Jersey

Emily S. Winn-Deen, Ph.D.

Celera Genomics
Rockville, Maryland

Freda E. Yoder, M.A.

National Institutes of Health
Rockville, Maryland

Advisors

Thomas W. Prior, Ph.D.

Ohio State University
Columbus, Ohio

Torbjorn Schroder

Eurona Medical
Eurona, Sweden

Jacqueline S. Scott, D.V.M., Ph.D.

Michigan Department of Public Health
Lansing, Michigan

Marc R. Schlank, M.T.(ASCP), M.S.
Staff Liaison

NCCLS
Wayne, Pennsylvania

Patrice E. Polgar
Editor

NCCLS
Wayne, Pennsylvania

Donna M. Wilhelm
Assistant Editor

NCCLS
Wayne, Pennsylvania

**Active Membership
(as of 1 January 2000)**

Sustaining Members

Abbott Laboratories
 American Association for
 Clinical Chemistry
 Bayer Corporation
 Beckman Coulter, Inc.
 BD and Company
 bioMérieux, Inc.
 College of American Pathologists
 Dade Behring Inc.
 Nippon Becton Dickinson Co., Ltd.
 Ortho-Clinical Diagnostics, Inc.
 Pfizer Inc
 Roche Diagnostics, Inc.

Professional Members

American Academy of Family
 Physicians
 American Association of Blood
 Banks
 American Association for
 Clinical Chemistry
 American Association for
 Respiratory Care
 American Chemical Society
 American Medical Technologists
 American Public Health Association
 American Society for Clinical
 Laboratory Science
 American Society of Hematology
 American Society for Microbiology
 American Society of
 Parasitologists, Inc.
 American Type Culture
 Collection, Inc.
 Asociación Española Primera de
 Socorros (Uruguay)
 Asociacion Mexicana de
 Bioquímica Clínica A.C.
 Assn. of Public Health Laboratories
 Assoc. Micro. Clinici Italiani-
 A.M.C.L.I.
 Australasian Association of
 Clinical Biochemists
 British Society for Antimicrobial
 Chemotherapy
 Canadian Society for Medical
 Laboratory Science-Société
 Canadienne de Science de
 Laboratoire Médical

Canadian Society of Clinical
 Chemists
 Clinical Laboratory Management
 Association
 College of American Pathologists
 College of Medical Laboratory
 Technologists of Ontario
 College of Physicians and
 Surgeons of Saskatchewan
 Commission on Office
 Laboratory Accreditation
 Danish Society of Clinical
 Chemistry
 Fundacion Bioquímica de la
 Provincia (Argentina)
 International Association of
 Medical Laboratory
 Technologists
 International Council for
 Standardization in Haematology
 International Federation of
 Clinical Chemistry
 International Society for
 Analytical Cytology
 Italian Society of Clinical
 Biochemistry
 Japan Society of Clinical Chemistry
 Japanese Association of
 Medical Technologists (Tokyo)
 Japanese Committee for Clinical
 Laboratory Standards
 Joint Commission on Accreditation
 of Healthcare Organizations
 National Academy of Clinical
 Biochemistry
 National Society for
 Histotechnology, Inc.
 Ontario Medical Association
 Laboratory Proficiency Testing
 Program
 Ordre professionnel des
 technologistes médicaux du
 Québec
 RCPA Quality Assurance
 Programs PTY Limited
 Sociedade Brasileira de Analises
 Clinicas
 Sociedade Brasileira de
 Patologia Clínica
 Sociedad Espanola de Química
 Clínica

Government Members

Armed Forces Institute of Pathology
 Association of Public Health
 Laboratory Directors
 BC Centre for Disease Control
 Centers for Disease Control and
 Prevention
 Chinese Committee for Clinical
 Laboratory Standards
 Commonwealth of Pennsylvania
 Bureau of Laboratories
 Department of Veterans Affairs
 Deutsches Institut für Normung
 (DIN)
 FDA Center for Devices and
 Radiological Health
 FDA Division of Anti-Infective
 Drug Products
 Health Care Financing
 Administration/CLIA Program
 Health Care Financing
 Administration
 Iowa State Hygienic Laboratory
 Massachusetts Department of
 Public Health Laboratories
 Michigan Department of
 Public Health
 National Association of Testing
 Authorities – Australia
 National Center of Infectious
 and Parasitic Diseases (Bulgaria)
 National Institute of Standards
 and Technology
 Ohio Department of Health
 Oklahoma State Department
 of Health
 Ontario Ministry of Health
 Saskatchewan Health-
 Provincial Laboratory
 Scientific Institute of Public
 Health; Belgium Ministry of
 Social Affairs, Public Health
 and the Environment
 South African Institute for
 Medical Research
 Swedish Institute for Infectious
 Disease Control
 Thailand Department of Medical
 Sciences

Industry Members

AB Biodisk
 Abbott Laboratories
 Accumetrics, Inc.
 Amersham Pharmacia Biotech
 Ammirati Regulatory Consulting
 Assessor
 AstraZeneca
 Aventis
 Avocet Medical, Inc.
 Bayer Corporation - Elkhart, IN
 Bayer Corporation - Middletown, VA
 Bayer Corporation - Tarrytown, NY
 Bayer Corporation - West Haven, CT
 Bayer Medical Ltd.
 Beckman Coulter, Inc.
 Beckman Coulter, Inc. Primary Care Diagnostics
 Beckman Coulter K.K. (Japan)
 BD and Company
 BD Biosciences
 BD Consumer Products
 BD Immunocytometry Systems
 BD Italia S.P.A.
 BD VACUTAINER Systems
 Biolog, Inc.
 bioMérieux, Inc.
 Biometrology Consultants
 Bio-Rad Laboratories, Inc.
 Biotest AG
 Bristol-Myers Squibb Company
 Canadian Reference Laboratory Ltd.
 CASCO•NERL Diagnostics
 Checkpoint Development Inc.
 Clinical Lab Engineering
 COBE Laboratories, Inc.
 Combact Diagnostic Systems Ltd.
 Community Medical Center (NJ)
 Control Lab (Brazil)
 Copan Diagnostics Inc.
 Cosmetic Ingredient Review
 Cubist Pharmaceuticals
 Cytometrics, Inc.
 Dade Behring Inc. - Deerfield, IL
 Dade Behring Inc. - Glasgow, DE
 Dade Behring Inc. - Marburg, Germany
 Dade Behring Inc. - Sacramento, CA
 Dade Behring Inc. - San Jose, CA
 DAKO A/S
 Diagnostic Products Corporation
 DiaSorin
 Eiken Chemical Company, Ltd.
 Enterprise Analysis Corporation

Fort Dodge Animal Health
 Gen-Probe
 Glaxo-Wellcome, Inc.
 Greiner Mediatech, Inc.
 Health Systems Concepts, Inc.
 Helena Laboratories
 Home Diagnostics, Inc.
 Hycor Biomedical Inc.
 I-STAT Corporation
 Instrumentation Laboratory
 Integ, Inc.
 International Technidyne Corporation
 Johnson City Medical Center
 Kendall Sherwood-Davis & Geck
 Labtest Diagnostica S.A.
 LifeScan, Inc. (a Johnson & Johnson Company)
 Lilly Research Laboratories
 Medical Device Consultants, Inc.
 Medical Laboratory Automation Inc.
 MediSense Products (Div. of Abbott Laboratories)
 Medtronic Perfusion Systems
 Merck & Company, Inc.
 mvi Sciences (MA)
 Nabi
 Neometrics Inc.
 Nichols Institute Diagnostics (Div. of Quest Diagnostics, Inc.)
 Nissui Pharmaceutical Co., Ltd.
 Nippon Becton Dickinson Co., Ltd.
 Norfolk Associates, Inc.
 OBC Associates
 Olympus Corporation
 Optical Sensors, Inc.
 Organon Teknika Corporation
 Ortho-Clinical Diagnostics, Inc. (England)
 Ortho-Clinical Diagnostics, Inc. (Raritan, NJ)
 Ortho-Clinical Diagnostics, Inc. (Rochester, NY)
 Oxoid Inc.
 Pfizer Inc
 Pharmacia & Upjohn
 Procter & Gamble
 Pharmaceuticals, Inc.
 The Product Development Group
 Quest Diagnostics Incorporated
 Quintiles, Inc.
 Radiometer America, Inc.
 Radiometer Medical A/S
 David G. Rhoads Associates, Inc.
 Roche Diagnostics GmbH
 Roche Diagnostics, Inc.

Roche Laboratories (Div. Hoffmann-La Roche Inc.)
 The R.W. Johnson Pharmaceutical Research Institute
 Sanofi Diagnostics Pasteur
 Sarstedt, Inc.
 SARL Laboratoire Carron (France)
 Schering Corporation
 Schleicher & Schuell, Inc.
 Second Opinion
 SenDx Medical, Inc.
 Showa Yakuhin Kako Company, Ltd.
 SmithKline Beecham, S.A.
 Streck Laboratories, Inc.
 Sysmex Corporation (Japan)
 Sysmex Corporation (Long Grove, IL)
 The Toledo Hospital (OH)
 Trek Diagnostic Systems, Inc.
 Vetoquinol S.A.
 Vysis, Inc.
 Wallac Oy
 Warner-Lambert Company
 Wyeth-Ayerst
 Xyletech Systems, Inc.
 YD Consultant

Trade Associations

Association of Medical Diagnostic Manufacturers
 Health Industry Manufacturers Association
 Japan Association Clinical Reagents Ind. (Tokyo, Japan)
 Medical Industry Association of Australia

Associate Active Members

67th CSH Wuerzburg, GE (NY)
 121st General Hospital (CA)
 Acadiana Medical Laboratories, LTD (LA)
 Advocate Laboratories (IL)
 Albany Medical Center Hospital (NY)
 Allegheny General Hospital (PA)
 Allegheny University of the Health Sciences (PA)
 Allina Laboratories (MN)
 Alton Ochsner Medical Foundation (LA)
 American Medical Laboratories (VA)
 Anzac House (Australia)

Asan Medical Center (Korea)	Elmhurst Memorial Hospital (IL)	John Peter Smith Hospital (TX)
Associated Regional & University Pathologists (UT)	Elyria Memorial Hospital (OH)	John Randolph Hospital (VA)
Aurora Consolidated Laboratories (WI)	Emory University Hospital (GA)	Johns Hopkins Medical Institutions (MD)
Baystate Medical Center (MA)	Fairfax Hospital (VA)	Johnson City Medical Center (IN)
Brantford General Hospital (Brantford, ON, Canada)	Fairview-University Medical Center (MN)	Kaiser Permanente (CA)
Brazileiro De Promocao (Brazil)	Foothills Hospital (Calgary, AB, Canada)	Kaiser Permanente (NC)
Bristol Regional Medical Center (TN)	Fox Chase Cancer Center (PA)	Kantousspital (Switzerland)
Brookdale Hospital Medical Center (NY)	Franklin Square Hospital Center (MD)	Klinicni Center (Slovenia)
Brooke Army Medical Center (TX)	Fresenius Medical Care/Life Chem (NJ)	LabCorp (NC)
Brooks Air Force Base (TX)	Fresno Community Hospital and Medical Center	Laboratoire de Santé Publique du Quebec (Canada)
Broward General Medical Center (FL)	Gambro Healthcare Laboratory (FL)	Laboratório Fleury S/C Ltda. (Brazil)
Calgary Laboratory Services (Calgary, AB, Canada)	GDS Technology, Inc (IN)	Laboratory Corporation of America (MO)
Carilion Consolidated Laboratory (VA)	Grady Memorial Hospital (GA)	Lakeland Regional Medical Center (FL)
CB Healthcare Complex (Sydney, NS, Canada)	Greater Southeast Community Hospital (DC)	Lancaster General Hospital (PA)
Central Kansas Medical Center	Guthrie Clinic Laboratories (PA)	Langley Air Force Base (VA)
Centro Diagnostico Italiano (Milano, Italy)	Halifax Medical Center (FL)	Lewis-Gale Medical Center (VA)
Champlain Valley Physicians Hospital (NY)	Harris Methodist Fort Worth (TX)	Libero Instituto Univ. Campus BioMedico (Italy)
Children's Hospital (LA)	Harris Methodist Northwest (TX)	LAC and USC Healthcare Network (CA)
Children's Hospital Medical Center (Akron, OH)	Hartford Hospital (CT)	Louisiana State University Medical Center
Children's Hospital of Philadelphia (PA)	Hays Pathology Laboratories, P.A. (KS)	Lutheran Hospital (WI)
Clendo Lab (Puerto Rico)	Health Alliance Laboratory (OH)	Massachusetts General Hospital (Microbiology Laboratory)
CLSI Laboratories (PA)	Health Network Lab (PA)	Massachusetts General Hospital (Pathology Laboratory)
Commonwealth of Kentucky	Health Sciences Centre (Winnipeg, MB, Canada)	Mayo Clinic Scottsdale (AZ)
Commonwealth of Virginia (DCLS)	Heartland Health System (MO)	MDS Metro Laboratory Services (Burnaby, BC, Canada)
CompuNet Clinical Laboratories (OH)	Hinsdale Hospital (IL)	Medical Center of Southern Indiana
Consolidated Laboratory Services (CA)	Hoag Memorial Hospital Presbyterian (CA)	Medical College of Virginia Hospital
Danville Regional Medical Center (VA)	Holmes Regional Medical Center (FL)	Melrose-Wakefield Hospital (MA)
Dean Medical Center (WI)	Holy Spirit Hospital (PA)	Memorial Hospital (CO)
Delaware Public Health Laboratory	Holzer Medical Center (OH)	Memorial Medical Center (Napoleon Ave., New Orleans, LA)
Detroit Health Department (MI)	Hospital for Sick Children (Toronto, ON, Canada)	Memorial Medical Center (N. Jefferson Davis Pkwy., New Orleans, LA)
Diagnostic Laboratory Services, Inc. (HI)	Hospital Israelita Albert Einstein (Brazil)	Memorial Medical Center (IL)
Duke University Medical Center (NC)	Hotel Dieu Hospital (Windsor, ON, Canada)	Mercy Health System (PA)
Durham Regional Hospital (NC)	Huddinge University Hospital (Sweden)	Mercy Hospital (NC)
Duzen Laboratories (Turkey)	Hurley Medical Center (MI)	Methodist Hospital (TX)
Dynacare Laboratories - Eastern Region (Ottawa, ON, Canada)	Indiana University	Methodist Hospital Indiana
E.A. Conway Medical Center (LA)	Instituto Scientifico HS. Raffaele (Italy)	Methodist Hospitals of Memphis (TN)
	International Health Management Associates, Inc. (IL)	Mid Michigan Medical Center - Midland
	Intermountain Health Care Laboratory Services (UT)	
	Jacobi Medical Center (NY)	

Montreal Children's Hospital (Canada)	St. Boniface General Hospital (Winnipeg, Canada)	University of Alberta Hospitals (Canada)
Montreal General Hospital (Canada)	St. Elizabeth Hospital (NJ)	University of Chicago Hospitals (IL)
Mount Sinai Hospital (NY)	St. John Hospital and Medical Center (MI)	University Hospital (IN)
National University Hospital (Singapore)	St. John Regional Hospital (St. John, NB, Canada)	University Hospital (Gent) (Belgium)
Naval Surface Warfare Center (IN)	St. Joseph Medical Center (MD)	University Hospital (London, Ontario, Canada)
Nebraska Health System	St. Joseph Hospital (NE)	The University Hospitals (OK)
New Britain General Hospital (CT)	St. Joseph Mercy – Oakland (MI)	University of Massachusetts Lowell
New England Medical Center Hospital (MA)	St. Joseph's Hospital - Marshfield Clinic (WI)	University of Medicine & Dentistry, NJ University Hospital
The New York Blood Center	St. Luke's Hospital (PA)	University of Michigan
The New York Hospital Medical Center of Queens	St. Luke's Regional Medical Center (IA)	University of the Ryukyus (Japan)
New York State Department of Health	St. Mary Hospital (NJ)	University of Virginia Medical Center
NorDx (ME)	St. Mary Medical Center (IN)	University of Washington
North Carolina Laboratory of Public Health	St. Mary of the Plains Hospital (TX)	UPMC Bedford Memorial (PA)
North Carolina School of Veterinary Medicine	Salina Regional Health Center (KS)	USAF Medical Center (OH)
Northridge Hospital Medical Center (CA)	San Francisco General Hospital (CA)	UZ-KUL Medical Center (Belgium)
Northwestern Memorial Hospital (IL)	Santa Cabrini Hospital (Montreal, PQ Canada)	VA (Dayton) Medical Center (OH)
Olin E. Teague Medical Center (TX)	Santa Clara Valley Medical Center (CA)	VA (Denver) Medical Center (CO)
Our Lady of Lourdes Hospital (NJ)	Seoul Nat'l University Hospital (Korea)	VA (Martinez) Medical Center (CA)
Our Lady of the Resurrection Medical Center (IL)	Shanghai Center for the Clinical Laboratory (China)	VA (San Diego) Medical Center (CA)
Pathology and Cytology Laboratories, Inc. (KY)	Shands Healthcare (FL)	VA (Tuskegee) Medical Center (AL)
The Permanente Medical Group (CA)	SmithKline Beecham Clinical Laboratories (GA)	VA Outpatient Clinic (OH)
Pocono Hospital (PA)	SmithKline Beecham Clinical Laboratories (WA)	Vejle Hospital (Denmark)
Presbyterian Hospital of Dallas (TX)	South Bend Medical Foundation (IN)	Via Christi Regional Medical Center (KS)
Providence Health System (OR)	Southern California Permanente Medical Group	Viridae Clinical Sciences, Inc. (Vancouver, BC, Canada)
Providence Medical Center (WA)	South Western Area Pathology Service (Australia)	Walter Reed Army Institute of Research (MD)
Queen Elizabeth Hospital (Prince Edward Island, Canada)	Speare Memorial Hospital (NH)	Warde Medical Laboratory (MI)
Queensland Health Pathology Services (Australia)	Speciality Laboratories, Inc. (CA)	Warren Hospital (NJ)
Quintiles Laboratories, Ltd. (GA)	Stanford Health Services (CA)	Washoe Medical Center (NV)
Regions Hospital	Stormont-Vail Regional Medical Center (KS)	Watson Clinic (FL)
Research Medical Center (MO)	Sun Health-Boswell Hospital (AZ)	Wilford Hall Medical Center (TX)
Riyadh Armed Forces Hospital (Saudi Arabia)	Sunrise Hospital and Medical Center (NV)	William Beaumont Hospital (MI)
Robert F. Kennedy Medical Center (CA)	Sutter Health (CA)	Williamsburg Community Hospital (VA)
Royal Columbian Hospital (New Westminster, BC, Canada)	Tampa General Hospital (FL)	Wilson Memorial Hospital (NY)
Saint Mary's Regional Medical Center (NV)	Tripler Army Medical Center (HI)	Winchester Hospital (MA)
St. Alexius Medical Center (ND)	Tulane Medical Center Hospital & Clinic (LA)	Winn Army Community Hospital (GA)
St. Anthony Hospital (CO)	UCSF Medical Center (CA)	Wishard Memorial Hospital (IN)
	UNC Hospitals (NC)	Womack Army Medical Center (NC)
	Unilab Clinical Laboratories (CA)	Yonsei University College of Medicine (Korea)
		York Hospital (PA)
		Zale Lipshy University Hospital (TX)

OFFICERS

William F. Koch, Ph.D.,
President
National Institute of Standards
and Technology

F. Alan Andersen, Ph.D.,
President Elect
Cosmetic Ingredient Review

Robert F. Moran, Ph.D.,
FCCM, FAIC
Secretary
mvi Sciences

Donna M. Meyer, Ph.D.,
Treasurer
CHRISTUS Health

A. Samuel Koenig, III, M.D.,
Past President
Family Medical Care

John V. Bergen, Ph.D.,
Executive Director

BOARD OF DIRECTORS

Sharon S. Ehrmeyer, Ph.D.
University of Wisconsin

Robert L. Habig, Ph.D.
Cytometrics, Inc.

Thomas L. Hearn, Ph.D.
Centers for Disease Control
and Prevention

Gerald A. Hoeltge, M.D.
The Cleveland Clinic Foundation

Elizabeth D. Jacobson, Ph.D.
FDA Center for Devices and
Radiological Health

Carolyn D. Jones, J.D., M.P.H.
Health Industry Manufacturers
Association

Hartmut Jung, Ph.D.
Roche Diagnostics GmbH

Tadashi Kawai, M.D., Ph.D.
International Clinical Pathology
Center

Barbara G. Painter, Ph.D.
Bayer Corporation

Marianne C. Watters,
M.T.(ASCP)
Parkland Health & Hospital
System

Ann M. Willey, Ph.D.
New York State Department of
Health

Judith A. Yost, M.A. M.T., (ASCP)
Health Care Financing
Administration

Contents

Abstract.....i

Committee Membership.....v

Active Membershipvii

Foreword.....xvii

1 Introduction1

 1.1 Diagnostic Utility1

 1.2 Advantages and Disadvantages1

 1.3 Ethical Considerations2

 1.4 Confidentiality.....2

2 Scope.....2

3 Definitions3

4 Nomenclature.....7

 4.1 Nomenclature for Designation of Mutations.....7

 4.2 Human Pedigree Nomenclature.....9

5 Safety.....10

 5.1 Standard Precautions.....10

 5.2 Biological Hazards10

 5.3 Chemical Hazards.....10

 5.4 Radiation Hazards11

 5.5 Ultraviolet Light Hazards.....11

 5.6 Electrical Hazards.....11

6 Intake Information.....11

 6.1 Family History and Clinical Data.....11

 6.2 Informed Consent12

7 Specimen Identification and Accessioning.....12

 7.1 Specimen Types.....12

 7.2 Specimen Identification12

 7.3 Requisition Forms.....13

 7.4 Criteria for Rejecting Specimens.....13

 7.5 Accessioning Specimens.....13

 7.6 Specimen Transport and Storage.....13

 7.7 Specimen Retention14

8 Sample Preparation and Processing14

 8.1 Target Nucleic Acid Release.....14

 8.2 Quality and Quantity of Nucleic Acid15

 8.3 Storage of Nucleic Acids16

 8.4 Inhibitors and Interfering Substances16

Contents (Continued)

9	Mutation Detection and Characterization.....	17
9.1	Deletion Detection.....	17
9.2	Point Mutation Detection.....	18
9.3	Short Tandem Repeats and Triplet Repeats.....	18
9.4	Unknown or Not Yet Sequenced Mutations.....	18
10	Southern Blots.....	21
10.1	General Information.....	21
10.2	Digesting Genomic DNA with Restriction Endonucleases.....	21
10.3	Preparation of Southern Blots.....	22
10.4	Probes.....	23
10.5	Membrane Hybridization.....	24
11	Nucleic Acid Amplification Technologies.....	26
11.1	Target (PCR, TAS, 3SR, SDA, and NASBA) Amplification.....	27
11.2	Probe Amplification.....	29
11.3	Signal Amplification.....	29
12	Controlling False-Positive Nucleic Acid Target Amplification Reactions.....	30
12.1	Reagents and Solutions.....	30
12.2	Pipettors.....	30
12.3	Laboratory Practices.....	30
12.4	Selection and Preparation of Controls.....	31
12.5	Laboratory Design.....	31
12.6	Amplification Product Inactivation Methods.....	32
13	Detection Formats.....	35
13.1	Flat-bed Gel Electrophoresis.....	35
13.2	Sequencing Gel Format Separation.....	35
13.3	Solid Phase (Blots, Wells, Beads).....	36
13.4	DNA Sequencing.....	36
14	Test Validation and Characterization.....	37
14.1	Characterize the Target Locus/Allele/Mutation Being Detected by the Test.....	38
14.2	Method/Procedure Validation.....	38
14.3	Assess Performance Properties of the Test.....	39
14.4	Limitations.....	42
14.5	Test Results.....	43
14.6	Verification of Established Procedure.....	43
15	Quality Assurance/Quality Control.....	43
15.1	Test Reagents/Reagent Quality Control Program.....	43
15.2	Equipment Calibration and Maintenance.....	44
15.3	Proficiency Testing.....	44
15.4	Positive Controls.....	44
16	Laboratory Results Reporting.....	45
16.1	Confidentiality.....	45
16.2	Records.....	45
16.3	Reports.....	46

Contents (Continued)

17 Selection of Referral Laboratories46

References48

Additional References.....53

Appendix.....55

Figure 1. Schematic of the Southern Blotting Method.55

Figure 2. PCR Amplification.....56

Figure 3. 3SR Amplification..57

Figure 4. Strand Displacement Amplification (SDA).....58

Figure 5. Q-beta Replicase59

Figure 6. Ligase Amplification of a Target by Use of Two Oligonucleotide Probes.60

Figure 7. Branched DNA Signal Amplification.61

Figure 8. Schematic of the Sanger Dideoxy Sequencing Method.62

Summary of Comments and Subcommittee Responses.....63

Summary of Delegate Voting Comments and Subcommittee Responses.....68

Related NCCLS Publications80

Related NCCLS Projects in Development81

Foreword

Molecular genetics has now become firmly entrenched as the third major subdiscipline of clinical laboratory medical genetics, emerging more recently than the other subspecialties — biochemical genetics and cytogenetics. Just as with any diagnostic method or test, in order to fully benefit the patient, it must be developed and practiced under appropriate conditions. Thus, the purpose of this guideline is to define conditions and principles which will optimize the provision of accurate genetic information while minimizing potential harm to the patient or family.

An important aspect of the development of this and all NCCLS documents should be emphasized, and that is the consensus process. Within the context and operation of NCCLS, the term “consensus” means more than agreement. In the context of guideline development, “consensus” is a process by which NCCLS, its members, and interested parties: 1) have the opportunity to review and to comment on any NCCLS publication, and 2) are assured that their comments will be given serious, competent consideration. In producing MM1-A, the intention of the NCCLS Subcommittee on Molecular Genetics was to reach a consensus so an approved guideline can be distributed to laboratories that use molecular diagnostic tests. The subcommittee also intended for the document to be broad in perspective and, thus, an educational resource for medical genetics.

Note that the following trade names are included in this document—Polaroid™; GeneTests.™ It is NCCLS policy to avoid using trade names unless the products identified are the only ones available. Trade names may also be used if they make it significantly easier for the reader to understand and follow the consensus document, as long as all relevant trade names are included.

Key Words

Amplification, gene, genetic disease, molecular diagnostic test, mutation detection, nucleic acid, Southern blot

Acronyms/Abbreviations

ARMS	amplification refractory mutation system
ASO	allele-specific oligonucleotide
bDNA	branched DNA
cDNA	complementary DNA
DGGE	denaturing gradient gel electrophoresis
DNA	deoxyribonucleic acid
dATP	deoxyadenine 5' triphosphate
dCTP	deoxycytidine 5' triphosphate
dGTP	deoxyguanine 5' triphosphate
dNTPs	deoxyribonucleoside triphosphates
dTTP	deoxythymidine 5' triphosphate
dUTP	deoxyuridine 5' triphosphate
ddATP	dideoxyadenine 5' triphosphate
ddCTP	dideoxycytidine 5' triphosphate
ddGTP	dideoxyguanine 5' triphosphate
ddTTP	dideoxythymidine 5' triphosphate
dsDNA	double-stranded DNA
EDTA	ethylene diaminetetracetic acid
LCR	ligase chain reaction
NASBA	nucleic acid sequence-based amplification
PCR	polymerase chain reaction
RFLP	restriction fragment length polymorphism

RNA	ribonucleic acid
RT-PCR	reverse transcriptase-polymerase chain reaction
SDA	strand displacement amplification
SDS	sodium dodecyl sulfate
SSCP	single-stranded conformational polymorphism
STR	short tandem repeat
TAE	tris-acetate-EDTA
TAS	transcription-based amplification system
TBE	tris-borate-EDTA
TE	tris-EDTA
UNG	uracil-N-glycosylase

Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline

1 Introduction

1.1 Diagnostic Utility

The identification, mapping, cloning, and sequencing of numerous genes associated with inherited diseases, and the advent of powerful methods for molecular analysis of these genes in clinical specimens, has revolutionized the practice of medical genetics. With these methods it is now possible to diagnose disease in at-risk individuals prior to the onset of symptoms, to screen for asymptomatic carriers of recessive traits, and to perform prenatal diagnosis even for those diseases which are not expressed in utero. In contrast to the other three major areas of clinical molecular biology—molecular microbiology, molecular oncology, and DNA forensics—where DNA-based techniques supplement or supplant more traditional diagnostic methods, molecular genetic techniques are often the only approach available for the applications cited. As such, they offer a powerful new tool for diagnosis, genetic counseling, and prevention of heritable disease.

1.2 Advantages and Disadvantages

DNA-based tests represent the most fundamental and definitive approach to the diagnosis of genetic diseases which are, by definition, due to lesions in an individual's DNA: nucleotide substitutions, deletions, insertions, duplications, expansions, and inversions. When these lesions are inherited from one or both parents, they are germline defects, present from conception and found in every DNA-containing cell of the body.^a Unlike molecular diagnosis of neoplasia or infectious disease, which requires DNA sampling of the tumor or infection site, molecular genetic diagnosis can be performed on any accessible body tissue. Even if the biochemical defect is only expressed in a particular inaccessible organ (e.g., the liver), diagnosis can be made using peripheral leukocytes, amniocytes, or any other convenient cell. Where prenatal biochemical diagnosis of phenylketonuria and sickle cell anemia formerly would have required such invasive techniques as fetal liver biopsy and fetal blood sampling, respectively, molecular analysis can now be done on amniocentesis or chorionic villus specimens. Moreover, target amplification techniques such as the polymerase chain reaction (PCR) render even the most minute samples adequate substrates for genetic analysis, leading to sample collection techniques even less invasive than simple phlebotomy: mouthwash, buccal scrapings, random urine collection, dried blood spots, and hair bulb analysis are all viable approaches for obtaining sufficient nucleated cells for mutation detection. In the foreseeable future, the ability to detect and analyze scarce fetal cells circulating in the maternal blood may even render amniocentesis and chorionic villus sampling obsolete. Single-cell genetic analysis may also make preimplantation diagnosis and other applications more commonplace.

The tremendous power of molecular genetic diagnosis brings with it unprecedented clinical, ethical and legal dilemmas and responsibilities. Because this discipline examines the patient's own constitutional genetic makeup, rather than the foreign DNA sequences of an invading microorganism or the secondarily altered genetic complement of a malignancy, the discovery of abnormality, especially in asymptomatic individuals, carries potential risks and liabilities. Identified carriers of mutations, even recessive ones, may become anxious, depressed, or socially stigmatized. They may be discriminated against by employers and health insurers. Presymptomatic diagnosis of severe, untreatable, late-onset disorders such as Huntington disease may be emotionally devastating, even resulting in suicide. Prenatal diagnosis of an affected fetus may lead to the difficult decision to terminate the pregnancy, with all the social, ethical, and legal implications that this entails.

^a The two sources of human cellular DNA, nuclei and mitochondria, are absent from mature erythrocytes.